Assumes timely access to ADAMTS13 testing and clinical diagnosis based on high likelihood of aTTP/iTTP. In de novo patients ... only some aspects of the disease. The triple threat of aTTP deserves ...

The ADAMTS13 antigen is not evaluated in clinical practice on a routine basis; however, ADAMTS13 depletion is associated with the severity of iTTP, due to fatal disease outcomes and a 5-fold ...

The deficiency of ADAMTS13 is referred to as acquired TTP (aTTP) and is immune-mediated (iTTP) most often by anti-ADAMTS13 autoantibodies; unidentified pathophysiology (uTTP) makes up about 20% of ...

A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura. A team led by investigators from ...